711.50
-11.50
(-1.59%)
May 23 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 707.83 - 719.00 |
| 52 week | 460.25 - 791.50 |
| Open | 715.50 |
| Vol. | 75,046.00 |
| Mkt cap | 619.52M* |
| P/E | 43.31 |
| Div/yield | 4.34/1.80* |
| EPS | 0.16* |
| Shares | 87.07M |
| Beta | - |
| Inst. own | - |
| *GBP |
Events
Jul 4, 2013
Dechra Pharmaceuticals PLC Interim Management Statement
Feb 26, 2013
Interim 2013 Dechra Pharmaceuticals PLC Earnings Conference Call
Feb 26, 2013
Interim 2013 Dechra Pharmaceuticals PLC Earnings Release
|
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | 3.41% | 2.76% |
| Operating margin | 5.97% | 4.87% |
| EBITD margin | - | 9.41% |
| Return on average assets | 4.34% | 3.48% |
| Return on average equity | 10.94% | 9.32% |
| Employees | 1,042 | - |
| Carbon Disclosure Rating | - | - |
Address
Dechra House Jamage Industrial Estate, Talke Pits Talke Pits
STOKE-ON-TRENT, ENG ST7 1XW
United Kingdom - Map
+44-1782-771100 (Phone)
+44-1782-773366 (Fax)
STOKE-ON-TRENT, ENG ST7 1XW
United Kingdom - Map
+44-1782-771100 (Phone)
+44-1782-773366 (Fax)
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
Dechra Pharmaceuticals PLC (Dechra) is a holding company. The Company operates in four segments: Product Development, European Pharmaceuticals, US Pharmaceuticals and Services. European Pharmaceuticals markets and sells pharmaceuticals and specialist pet foods to the veterinary profession in Europe. It comprises Dechra Veterinary Products Europe and Dechra manufacturing. US Pharmaceuticals markets and sells a range of endocrine, ophthalmic, dermatological and equine products into North America. It includes Dechra Veterinary Products US. Services segment distributes veterinary products, including pharmaceuticals, specialist pet diets and instruments to veterinary practices within the United Kingdom. It also provides histology, pathology, haematology, chemistry and microbiology services to veterinary practices. In January 2012, Dechra acquired rights to HY-50. In May 2012, it acquired Eurovet Animal Health B.V.
Officers and directors
| Ian D. Page | Chief Executive, Executive Director | |
| Anne-Francoise Nesmes | Chief Financial Officer, Director | |
| Mike Eldred | President - US Operations, Dechra Veterinary Products | |
| Tony Griffin | Managing Director - Dechra Veterinary Products Europe, Executive Director | |
| Mike D. Annice | Managing Director - Dechra Manufacturing | |
| Peter Graham Ph.D. | Managing Director - Dechra Laboratory Services and Dechra Specialist Laboratories | |
| Martin Riley | Managing Director - National Veterinary Services | |
| Paul Sandland | Group Financial Controller | |
| Ed T. W. Torr | Director - Product and Business Development, Executive Director | |
| Barbara Johnson | Group Human Resources Director |